Epigenomics AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPGNF research report →
Companywww.epigenomics.com
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
- CEO
- Noel Thomas Doheny
- IPO
- 2010
- Employees
- 6
- HQ
- Heidelberg, DE
Price Chart
Valuation
- Market Cap
- $982.18K
- P/E
- -0.24
- P/S
- 1.26
- P/B
- 0.28
- EV/EBITDA
- 0.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.26%
- Op Margin
- -2484.74%
- Net Margin
- -2479.18%
- ROE
- -74.47%
- ROIC
- -107.86%
Growth & Income
- Revenue
- $23.99K · 0.00%
- Net Income
- $-313,882 · 90.95%
- EPS
- $-0.36 · 90.91%
- Op Income
- $-335,873
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $1.12
- 52W Low
- $0.79
- 50D MA
- $1.12
- 200D MA
- $1.03
- Beta
- 0.98
- Avg Volume
- 555.887
Get TickerSpark's AI analysis on EPGNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EPGNF Coverage
We haven't published any research on EPGNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EPGNF Report →